A randomised trial of zoledronic acid for osteoarthritis of the knee

唑来膦酸治疗膝骨关节炎的随机试验

• 批准号: nhmrc : 1045415
• 负责人: Dr Dawn Aitken
• 金额: $ 65.96万
• 依托单位: Antarctic Climate and Ecosystems CRC, University of Tasmania
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-trial-zoledronic-osteoarthritis-knee/111747
• 关键词: randomised; trial; zoledronic; acid; osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis and is increasing markedly due to an ageing population. Despite its large disease burden, there are currently no approved disease-modifying drugs available which modify structural progression of OA. The aim of this study is to compare zoledronic acid treatment to placebo on knee structural change and knee pain over two years. It is hypothesised that zoledronic acid will reduce cartilage loss, knee pain, and bone marrow lesion size.

骨关节炎（OA）是最常见的关节炎形式，并且由于人口老龄化而显着增加。尽管疾病负担很大，但目前还没有批准的疾病改善药物可以改变OA的结构进展。本研究的目的是比较唑来膦酸治疗和安慰剂治疗两年内对膝关节结构改变和膝关节疼痛的影响。据推测，唑来膦酸可以减少软骨丢失、膝关节疼痛和骨髓损伤的大小。